Tesaro’s ovarian cancer drug Zejula added to Cancer Drugs Fund
Drug is first PARP inhibitor shown to be effective in both patients with and without a BRCA mutation
Read More
Author: George Underwood
EMA facing higher-than-expected staff losses after Brexit
Executive Director Guido Rasi says that hitting 19% staff loss figure will be “very challenging”
Read More
Roche ends development of olesoxime after “many difficulties”
The company acquired the spinal muscular atrophy drug from Trophos for €120 million in 2015
Read More
Antibiotic supply chains on ‘brink of collapse’
Access to Medicine Foundation warns that urgent action is needed to rebuild the antibiotics market
Read More
Pfizer’s Xalkori makes it onto Cancer Drugs Fund
NICE has said that evidence is limited for the drug’s effectiveness in treating ROS1-positive lung cancer
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
